Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Researchers confirm using zebrafish that if a certain gene is not excluded when vertebrate embryos are developing, the notochord will not elongate properly, resulting in a shortened form.